Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)



Status:Terminated
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:40 - Any
Updated:10/14/2017
Start Date:November 26, 2013
End Date:October 27, 2016

Use our guide to learn which trials are right for you!

A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months

This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind
clinical trial followed by conversion of each arm to active nintedanib for an additional 6
months comparing the effect of nintedanib 150mg BID on the progression of IPF measured by
using HRCT, lung function, 6MWT, biomarkers, and PROs with continued treatment and
assessments for up to 18 months.


Inclusion criteria:

1. Written Informed Consent consistent with International Conference on Harmonisation
Good Clinical Practice (ICH-GCP) and local laws signed prior to entry into the study

2. Patient aged >= 40 years at Visit 1.

3. IPF diagnosed, according to the 2011 ATS/ERS/JRS/ALAT IPF guidelines for diagnosis and
management, within 5 years and reaffirmed applying 2011 Guidelines (P11-07084) if
diagnosed >2 years and up to 5 year from Visit 1,. Diagnosis must be confirmed by
chest HRCT taken within 24 months of Visit 1. All HRCT results reported to be possible
or inconsistent usual interstitial pneumonia (UIP) must have confirmatory pathology.

4. DLCO (corrected for Hb): 30%-79% predicted of normal

5. FVC >= 50% predicted of normal at Visit 1 and Visit 2

Exclusion criteria:

1. AST, ALT > 1.5 fold ULN

2. Bilirubin > 1.5 fold ULN

3. Bleeding risk:

1. Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g.
vitamin K antagonists, dabigatran, heparin, hirudin), or high dose antiplatelet
therapy. Exceptions: prophylactic low dose heparin or heparin flush as needed for
maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 IU s.c. per
day) and prophylactic use of antiplatelet therapy (e.g. acetyl salicylic acid up
to 325 mg/d, or clopidogrel at 75 mg/d, or equivalent doses of other antiplatelet
therapy)

2. History of hemorrhagic Central Nervous System (CNS) event within 12 months

3. Any of the following within 3 months:

- Haemoptysis or haematuria.

- Active gastro-intestinal bleeding or ulcers.

- Major injury or surgery.

4. Coagulation parameters: International normalised ratio (INR) > 2, prothrombin
time (PT) and partial thromboplastin time (PTT) > 150% of institutional ULN.

4. Planned major surgery within the next 3 months, including lung transplantation, major
abdominal or major intestinal surgery.

5. Thrombotic risk

1. Known inherited predisposition to thrombosis.

2. History of thrombotic event (including stroke and transient ischemic attacks)
within 12 months

6. Current or planned usage of any investigational drug during the course of this trial

7. Previous treatment with nintedanib within a clinical trial in the previous 3 months
and discontinuation of nintedanib study treatment due to an adverse event

8. Known hypersensitivity to the trial drug or its component

9. A disease or condition which in the opinion of investigator may put the patient at
risk because of participation in this trial or limit the patient's ability to
participate in this trial. Patients will be excluded if they require greater than
12L/min oxygen, are not ambulatory or require use of a walker or cane during the 6
Minute Titration Walk Test. Patients who cannot complete the 6 Minute Titration Walk
Test are excluded from participation.

10. Alcohol or drug abuse which in the opinion of the investigator would interfere with
trial participation.

11. Pregnant women or women who are breast feeding or of child bearing potential not using
two effective methods of birth control (one barrier and one highly effective
non-barrier) for at least 1 month prior to trial and/or not committing to using it
until 3 months after end of treatment.
We found this trial at
13
sites
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Danbury, CT
Click here to add this to my saved trials
?
mi
from
Edmonton,
Click here to add this to my saved trials
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Mineola, NY
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Skokie, IL
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials